Clinical Trial Update: Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS [Phase 2]

View source ↗

Summary

Phase II trial evaluating nivolumab with low-dose radiotherapy for incomplete responders with Hodgkin lymphoma is terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-06-28